Anaplastic astrocytomas: Biology and treatment

Expert Review of Neurotherapeutics

Volumn 8, Issue 4, 2008, Pages 575-586

  Chamberlain, Marc C ^a   Chowdhary, Sajeel A ^a,b   Glantz, Michael J ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Anaplastic astrocytoma; Malignant glioma; Primary brain tumor

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AP 23573; BEVACIZUMAB; CARMUSTINE; CETUXIMAB; CILENGITIDE; CYCLOPHOSPHAMIDE; DASATINIB; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; IRINOTECAN; LOMUSTINE; LONAFARNIB; PAZOPANIB; PERIFOSINE; PROCARBAZINE; RAPAMYCIN; RETINOIC ACID; SORAFENIB; TAMOXIFEN; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB; VATALANIB; VORINOSTAT;

BRAIN ANGIOGRAPHY; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 22Q; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DNA DAMAGE; DNA METHYLATION; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENOMIC INSTABILITY; GLIOBLASTOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ASTROCYTOMA; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 42249114829     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.4.575     Document Type: Review

References (72)

1. The Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J. Clin. Oncol. 19, 509-518 (2001). • Randomized trial of malignant gliomas comparing radiotherapy with or without procarbazine, CCNU and vincristine (PCV) chemotherapy as initial therapy that showed no benefit to adjuvant chemotherapy for either glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).
2. Prados MD, Scott C, Curran WJ et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J. Clin. Oncol. 17, 3389-3395 (1999). • Retrospective comparative study evaluating the effectiveness of adjuvant chemotherapy for AA, demonstrating no survival differences.
3. Westphal M, Hilt DC, Bortey E et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol. 5(2), 79-88 (2003).
4. Prados MD, Levin V. Biology and treatment of malignant glioma. Semin. Oncology 27(3 Suppl. 6), 1-10 (2000).
5. Gutin PH, Prados MD, Phillips TL et al. External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG Study 6G82-2. Int. J. Radiat. Oncol. Biol. Phys. 21, 601 (1991).
6. Loeffler JS, Alexander E, Shea WM et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J. Clin. Oncol. 10(9), 1379-1385 (1992).
7. Prados MD, Gutin PH, Phillips TL et al. Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience. Int. J. Radiat. Oncol. Biol. Phys. 24, 593 (1992).
8. Levin VA, Silver P, Hannigan J et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic giomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 18, 321-324 (1990).
9. Stewart LA. Chemotherapy in adult high-grade glioma: a systemic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359, 1011-1018 (2002). •• One of two meta-analyses demonstrating a 5-6% improvement in overall survival with the inclusion of adjuvant chemotherapy in malignant gliomas.
10. Fine HA, Dear KB, Loeffler JS et al. Meta-analysis of radiation therapy and without chemotherapy for malignant gliomas in adults. Cancer 71, 2585-2597 (1993).
11. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol. 17, 2572-2578 (1999). •• Retrospective evaluation of eight clinical trials in patients with recurrent malignant gliomas, demonstrating the value of progression-free survival at 6 months and establishing benchmarks for subsequent trials.
12. Yung WKA, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant gliomas: a Phase II study. J. Clin. Oncol. 9, 860 (1991).
13. Allen JC, Walker R, Luks E et al. Carboplatin and recurrent childhood brain tumors. J. Clin. Oncol. 759-763 (1987).
14. Yung WK, Prados MD, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J. Clin. Oncol. 17, 2762-2771 (1999). •• Largest prospective trial of temozolomide (TMZ) in the treatment of recurrent WHO grade III malignant gliomas, showing favorable palliative benefit.
15. Allen JC, Helson L. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J. Neurosurg. 55, 749-756 (1981).
16. Longee DC, Friedman HS, Albright RE et al. Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J. Neurosurg. 72, 583-588 (1990).
17. Prados MD, Gutin PH, Phillips TL et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int. J. Radiat. Oncol. Biol. Phys. 23, 3-8 (1992). "" Another retrospective review of AA indicating no benefit to the inclusion of adjuvant chemotherapy.
18. Tortosa A, Vinolas N, Villa S et al. Prognostic implications of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97, 1063-1071 (2003).
19. Levin VA, Hess KR, Choucair A et al. Phase III randomized study of postradiotherapy chemotherapy with combination-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin. Cancer Res. 9, 891-990 (2003).
20. Chang SM, Seiferheld W, Curran W et al. Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. Int. J. Radiat. Oncol. Biol. Phys. 59, 1122-1126 (2004).
21. Laramore GE, Martz KL, Nelson JS et al. Radiation Therapy Oncology Group (RTOG) survival data on anaplastic astrocytomas of the brain: does a more aggressive form of treatment adversely impact survival? Int. J. Radiat. Oncol. Biol. Phys. 17(6), 1351-1356 (1989).
22. Prados MD, Seiferheld W, Sandler HM et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int. J. Radiat. Oncol. Biol. Phys. 58, 1147-1152 (2004).
23. Levin VA, Prados MD, Yung WKA, Gleason MJ, Ictech S, Malec M. Treatment of recurrent gliomas with enflornithine. J. Natl Cancer Instit. 84, 1432-1437 (1992).
24. Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345, 1008-1012 (1995).
25. Levin VA, Prados MD. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosoureas resistance. J. Clin. Oncol. 10, 766-771 (1992).
26. Yung WKA, Kyritsis AP, Gleason MJ, Levin VA. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin. Cancer Res. 2, 1931-1935 (1996).
27. Chamberlain MC, Kormanik P. Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas. J. Clin. Oncol. 43, 71-78 (1999).
28. Chamberlain M, Tsao-Wei D, Blumenthal D, Glantz MJ. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma Cancer (2007) (In Press).
29. Chamberlain MC, Tsao-Wei D, Groshen S. Salvage chemotherapy with cyclophosphamide for temozolomide refractory anaplastic astrocytoma. Cancer 106(1), 172-179 (2006).
30. Pathology and genetics of tumors of the nervous system. In: World Health Organization Classification of Tumours of the Nervous System, Editorial and Consensus Conference Working Group. Kleihues P, Cavenee WK (Eds). IARC Press, Lyon, France (2007).
31. Ironside JW, Moss TH, Louis DN et al. Diagnostic Pathology of Nervous System Tumours. Churchill Livingstone, London, UK (2002).
32. Louis DN, Pomeroy SL, Cairncross JG. Focus on central nervous system neoplasia. Cancer Cell 1(2), 125-128 (2002).
33. Louis DN, Cavenee WK. Molecular biology of central nervous system tumors. In: Cancer: Principles and Practice of Oncology (Seventh Edition). DeVita VT Jr, Hellman S, Rosenberg SA (Eds). Lippincott-Raven, PA, USA (2004).
34. Louis DN. Molecular pathology of malignant glioma. Ann. Rev. Pathol. Mech. Dis. 1, 97-124 (2006).
35. Stemmer-Rachamimov AO, Louis DN, Nielsen GP et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res. 64, 3718-3724 (2004).
36. Zhu Y, Guignard F, Zhao D et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8, 119-130 (2005).
37. Galli R, Binda E, Orfanelli U et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 7011-7021 (2004).
38. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumor initiating cells. Nature 432, 396-401 (2004).
39. Watanabe K, Tachibana O, Sata K et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastoma. Brain Pathol. 6, 217-223 (1996).
40. Ueki K, Ono Y, Henson JW et al. CDKN2/p16 or RB alterations occur in the majority of glioblastoma and are inversely correlated. Cancer Res. 56, 150-153 (1996).
41. Fujisawa H, Kurrer M, Reis RM et al. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am. J. Pathol. 155, 387-394 (1999).
42. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphastase gene mutated in human brain, breast and prostate cancer. Science 275, 1943-1947 (1997).
43. Hermanson M, Funa K, Hartman M et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 52, 3213-3219 (1992).
44. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer 3, 489-501 (2003).
45. Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann. Intern. Med. 138, 659-668 (2003).
46. Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab. Invest. 84, 397-405 (2004).
47. Brat DJ, Castellano-Sanchez AA, Hunter SB et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res. 64, 920-927 (2004).
48. Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350-1354 (2000).
49. Hegi ME, Diserens AC, Godard S et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 10, 1841-1871 (2004).
50. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005). •• Substudy of the EORTC TMZ GBM trial indicating the favorable benefit with respect to survival in patients with low content of the MGMT protein.
51. Chang SM, Parney IF, Huang W et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 293, 557-564 (2005).
52. Kondziolka D, Bernstein M, Resch L et al. Significance of hemorrhage into brain tumors: clinicopathological study. J. Neurosurg. 67, 852-860 (1987).
53. Yung WA, Horten BC, Shapiro WR. Meningeal gliomatosis: a review of 12 cases. Ann. Neurol. 8, 605-609 (1980).
54. Chamberlain MC. Combined-modality treatment of leptomeningeal gliomatosis. Neurosurgery 52, 324-330 (2003).
55. Bragg DG, Osborn AG. CNS imaging of neoplasms. Int. J. Radiat. Oncol. Biol. Phys. 21, 841-860 (1991).
56. Jaeckle KA. Neuroimaging for central nervous system tumors. Semin. Oncol. 18, 150-158 (1991).
57. Brem SS, Bierman PJ, Black P et al. Central nervous system cancers: clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 3, 644-690 (2005).
58. Stupp R, Mason WP, van den Bent M et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005). •• Randomized trial by the EORTC defining a new standard of care for patients with newly diagnosed GBM.
59. Cairncross G, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Oncology Group trial 9402. J. Clin. Oncol. 24(18), 2707-2714 (2006). •• Randomized trial of AA showing no benefit (except with respect to patients with co-deleted tumors showing an improvement in progression-free survival) to neoadjuvant PCV chemotherapy in either nondeleted or co-deleted tumors.
60. van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine and vincristine improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer Phase III trial. J. Clin. Oncol. 24(18), 2715-2722 (2006). •• Randomized trial of anaplastic oligodendrogliomas showing no benefit to neoadjuvant PCV chemotherapy in either nondeleted or co-deleted tumors, that is, regardless of genotype.
61. Jaeckle KA, Hess KR, Yung WK et al. Phase II evaluation of temozolomide nd 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol. 21(12), 2305-2311 (2003).
62. Vrendenburgh JJ, Desjardins A, Herndon JE II et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 13(4), 1253-1259 (2007). •• Single-institution study demonstrating efficacy of antiangiogenic therapy in the treatment of recurrent WHO grade III malignant gliomas.
63. Batchelor TT, Sorensen AG, diTomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
64. Nabors LB, Mikkelsen T, Rosenfeld SS et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol. 25(13), 1651-1662 (2007).
65. Combs SE, Thilmann C, Edler L, Debus J, Schultz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J. Clin. Oncol. 23(34), 8863-8869 (2005).
66. Ulm AJ, Friedman WA, Bradshaw P, Fote KD, Bova FJ. Radiosurgery in the management of malignant gliomas: the University of Florida experience. Neurosurgery 57, 512-517 (2005).
67. Muller W, Afra D, Schroder R. Supratentorial recurrences of gliomas: morphological studies in relation to time intervals with astrocytomas. Acta Neurochir. (Wien) 37, 75-84 (1977).
68. Laws ER, Taylor WF, Clifton MB et al. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J. Neurosurg. 61, 665-673 (1984).
69. Piepmeier J, Christopher S, Spencer D et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 38, 872-878 (1996).
70. Schmidt MH, Berger MS, Lamborn KR et al. Repeated operations for infiltrative low-grade gliomas without intervening therapy. J. Neurosurg. 98(6), 1165-1169 (2003).
71. Brandes AA, Nicolardi L, Tosoni A et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro-Oncol. 8(3), 253-260 (2006).
72. Sathornsumetee S, Reardon D, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer 110, 113-124 (2007).